Ann: Quarterly Activities Report, page-117

Hi semi retired, the information I've posted is straight out of WKT's announcements.

As for a re-rate, the CRDB drawdown and H2 2022 commissioning was already priced into WKT's valuation when the stock's shares went into a TH and then subsequently suspended from trading. The only things that have changed is some progress on development, the Wogen sales agreement, and commissioning being pushed out till some time next year. If there is a reduction in the amount CRDB is willing to lend WKT I'm expecting a re-rate to the downside. If CRDB is still willing to lend US$20m on the same terms (8% interest rate + repayment grace period) then we may see some share price appreciation. BMCG haven't been able to realise any of their investment for two months already, so there's a chance that their selling could weigh on any share price appreciation once trading resumes.

Hopefully the replacement SBLC is resolved by 4th August and drawdown on the CRDB facility can commence. WKT can ill-afford further delays on the remaining equipment shipments.

Let's hope that the interim funding that shareholders are being tapped for isn't a high-interest short-term loan that will have to repaid via a capital raise.